SB 755, the Finn Sawyer Access to Cancer Testing Act, would require Medicare, Medicaid, and CHIP to cover certain cancer diagnostic and laboratory tests, including microarray analysis, DNA sequencing, RNA sequencing, whole-exome sequencing, and other next-generation sequencing, along with the interpretation of those results. For Medicare, the bill would add these tests as covered services, set payment at 80 percent of the lesser of the actual charge or the comparable clinical laboratory fee schedule amount, and exempt the tests from the Medicare deductible. It would also limit repeat coverage of the same genetic content to the time of diagnosis, recurrence, or when needed for treatment planning or monitoring.
The bill also directs Medicaid and CHIP to cover these cancer tests, with Medicaid coverage becoming effective for services furnished on or after January 1, 2027, and CHIP coverage beginning January 1, 2025. A state-legislation transition rule would give states additional time to conform their Medicaid plans if state law changes are needed. In addition, the bill creates a federal education and awareness program on genomic testing for physicians and the public, and encourages medical education on molecular diagnostics in oncology training.
The bill’s impact would be to expand access to precision oncology testing for patients with cancer across major public coverage programs and to standardize coverage of genomic and molecular diagnostics. It would amend the Social Security Act provisions governing Medicare, Medicaid, and CHIP, adding a new covered category of cancer diagnostic and laboratory tests and modifying payment and exclusion rules for Medicare. It would also create new federal education and training activities related to genomic testing and genetic counseling.
The available context shows no recorded committee debate or votes, so there is no documented partisan or stakeholder sentiment in the provided materials. Based on the bill text alone, the measure appears generally supportive of broader cancer testing access and clinician/public awareness, with the main policy design choices centered on coverage scope, payment methodology, and timing of implementation. Any contention would likely focus on federal spending, state Medicaid conformity, and whether the bill’s frequency limits on repeat testing are sufficiently flexible for clinical practice.
SB 755 would amend the Social Security Act to require coverage of specified cancer genomic and laboratory tests under Medicare, Medicaid, and CHIP, creating a new statutory category for these services and adjusting Medicare payment and deductible rules. It would also require Medicaid and CHIP coverage of these tests, with delayed implementation for Medicaid and a state-plan transition provision where state legislation is needed. The bill further establishes a federal education and awareness program on genomic testing and encourages oncology-related training on molecular diagnostics.
No committee transcript or vote record was provided, so there is no direct evidence of legislative sentiment in the available context. The bill text suggests a broadly pro-access, pro-innovation approach aimed at improving cancer diagnosis and treatment planning through genomic testing. The absence of recorded opposition or amendments means any controversy is not documented in the supplied materials.
The main potential points of contention are likely to be cost, federal-state implementation, and utilization controls. Coverage expansion in Medicare, Medicaid, and CHIP could raise spending concerns for federal and state programs, while the Medicaid transition language acknowledges that some states may need legislation to comply. Another possible issue is the bill’s limit on repeating the same genetic content, which may be viewed as either a prudent guardrail against unnecessary testing or too restrictive for complex cancer care. The education and training provisions are less likely to be controversial, but they still expand federal involvement in medical education and public awareness.